Elizabeth A. Mulligan

Suggest Changes
Learn More
PURPOSE Thirty percent of patients treated with curative intent for localized prostate cancer (PC) experience biochemical recurrence (BCR) with rising serum prostate-specific antigen (sPSA), and of(More)